Bad news for Eli Lilly (NYSE: LLY) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday ...

Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on January 13 and set a price target of ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

On Monday, Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.62 which represents a decrease of $-1.64 or -1.90% from the prior close of $86.26. The stock opened at $84.42 and touched a ...

We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

These stocks are all trading near their 52-week lows, and could be attractive options to consider. They all possess promising ...

Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Lilly authorized a $15 billion stock buyback on Dec 9, 2024 ... They have also proven to be superior to Novo Nordisk's ...

Pharmaceutical giant Eli Lilly & Co. (LLY) is buying privately held Scorpion Therapeutics’ experimental cancer therapy for $2 ...

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its ...